Hong Kong · Delayed Price · Currency is HKD Medtide Company Description
Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, preclinical research, clinical development, and commercial-stage production services.
It offers peptide new chemical entity discovery synthesis, peptide chemistry, manufacturing, and control development and commercial manufacturing services.
The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products.
Its research and development technology platform include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening.
It serves customers in China, the United States, Japan, Europe, South Korea, and Australia. The company was formerly known as Taide Pharmaceutical (Zhejiang) Co., Ltd and changed its name to Medtide Inc. in February 2023.
Medtide Inc. was incorporated in 2020 and is headquartered in Hangzhou, China.
| Country | China |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Qi Xu |
Contact Details
Address: No. 69, 12 Street Hangzhou, 310018 China | |
| Website | medtideinc.com |
Stock Details
| Ticker Symbol | 3880 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100006S86 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Dr. Qi Xu | Chief Executive Officer and Chairwoman |
| Tao Cheng EMBA | Chief Business Officer and Executive Director |
| Xiangli Li | Executive Director |
| Dr. Xiang Li | Executive Director |
| Lingmei Li | Joint Company Secretary, Secretary to Board and Executive Director |
| Weiqun Xu | Finance Director |
| Chung Shing Lee | Joint Company Secretary |